Skip to main content

Liquid Biopsies conference EACR

Visit our online booth to learn more about urine as a liquid biopsy in cancer research. Find out more about our unique urine collection & stabilization device, Colli-Pee and its potential in cervical, prostate, and breast cancer research. Feel free to chat to any of our representatives or watch our satellite symposium about urine as an emerging liquid biopsy. We look forward to seeing you there!

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.